The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Review of sertraline and its clinical applications in psychiatric disorders
Abstract
Sertraline (Zoloft, Pfizer) has been shown in numerous controlled studies to have similar efficacy to other selective serotonin (5-HT) re-uptake inhibitors (SSRIs) in the treatment of depression and anxiety disorders. Further research is indicating that the efficacy of sertraline extends even beyond the treatment of depression and anxiety to include utility in eating disorders, premenstrual dysphoric disorder (PMDD) and possibly substance abuse treatment. Along with other SSRIs, sertraline offers several advantages over older antidepressants, including improved patient tolerability, low risk of lethality in overdose and no dependence potential. In head-to-head comparisons, sertraline appears to be at least as well-tolerated as other SSRIs and may even have a more favourable side effect profile. Low potential for pharmacokinetic drug interactions is another advantage of sertraline. Unlike fluoxetine, fluvoxamine and paroxetine, sertraline is not a potent inhibitor of any of the cytochrome P450 isoenzyme systems. As a result of its proven efficacy, good tolerability and lack of pharmacokinetic interactions, sertraline should be considered first-line in the treatment of anxiety and depressive disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., & Farfel, G. M. (2000) · JAMA · doi:10.1001/jama.283.14.1837 · Cited by 690
Self-citationNeurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 458
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Fluoxetine in post‐traumatic stress disorder
Davidson, J., Roth, S., & Newman, E. (1991) · Journal of Traumatic Stress · doi:10.1002/jts.2490040309 · Cited by 412
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02754-9 · Cited by 368 · cited 1×
“A recent meta-analysis evaluating randomised, controlled trials of SSRIs for treatment of PMDD found all of the SSRIs to be effective with the exception of fluvoxamine [45].”
MethodFluoxetine in Depressed Alcoholics: A Double-blind, Placebo-Controlled Trial
Cornelius, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200024004 · Cited by 357
Fluoxetine in post-traumatic stress disorder: Randomised, double-blind study
Connor, K. M., Sutherland, S. M., Tupler, L. A., Malik, M. L., Jonathan, R., & Davidson, T. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.17 · Cited by 353
Serotonin Syndrome Presentation of 2 Cases and Review of the Literature
Mason, P. J., Morris, V. A., & Balcezak, T. J. (2000) · Medicine · doi:10.1097/00005792-200007000-00001 · Cited by 309
Cited by
Asymmetric Hydrogenation of Olefins Using Chiral Crabtree-type Catalysts: Scope and Limitations
Verendel, J. J., Pàmies, O., Diéguez, M., & Andersson, P. G. (2014) · Chemical Reviews · doi:10.1021/cr400037u · Cited by 505
Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity
Klaassens, B. L., van Gorsel, H. C., Khalili-Mahani, N., van der Grond, J., Wyman, B. T., Whitcher, B., Rombouts, S. A. R. B., & van Gerven, J. M. A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.08.012 · Cited by 76
Metadata
- Authors
- McRae, A. L., & Brady, K. T.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2001-05
- Volume
- 2
- Issue
- 5
- Pages
- 883-892
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2047176101
- Cited by
- 287
- References
- 78
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.